Attovia is a biotechnology company which offers therapeutic solutions to pharmaceutical companies and healthcare providers. Their platform utilizes a biparatopic nanobody approach in developing potential therapies for complex diseases. By focusing on previously untreatable conditions, Attovia strives to advance drug discovery and provide innovative solutions for unmet medical needs. This company was founded by Tao Fu, Yuling Luo Ph.D, Hangjun Zhan Ph.D, David Bellovin Ph.D, and Petter Veiby Ph.D in 2023 and is headquartered in Fremont, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/09/2024 | Series B | $105MM | $xx.xx | $273.65MM | Cormorant Asset Management, Ecor1 Capital, Frazier Life Sciences, Goldman Sachs Asset Management, Illumina Ventures, Logos Capital, Marshall Wace, Nextech Ventures, Redmile Group, Venbio Partners | |
Price per Share
$xx.xx
Shares Outstanding
76,363,636
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Cormorant Asset Management, Ecor1 Capital, Frazier Life Sciences, Goldman Sachs Asset Management, Illumina Ventures, Logos Capital, Marshall Wace, Nextech Ventures, Redmile Group, Venbio Partners
|
||||||
06/20/2023 | Series A-1 | $30.43MM | $xx.xx | $159.73MM | Frazier Life Sciences, Illumina Ventures, Venbio Partners | |
Price per Share
$xx.xx
Shares Outstanding
30,425,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Frazier Life Sciences, Illumina Ventures, Venbio Partners
|
||||||
06/20/2023 | Series A-2 | $30.42MM | $xx.xx | $159.73MM | Frazier Life Sciences, Illumina Ventures, Venbio Partners | |
Price per Share
$xx.xx
Shares Outstanding
27,659,090
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Frazier Life Sciences, Illumina Ventures, Venbio Partners
|